4M0R

Trianthranilate-like analogue bound to anthranilate phosphoribosyltransferase (AnPRT; TrpD).

4M0R の概要

• エントリーDOI: 10.2210/pdb4m0r/pdb
• 関連するPDBエントリー: 4GIU 4GKM 4IJ1
• 分子名称: Anthranilate phosphoribosyltransferase, 2,6-bis[(2-carboxyphenyl)amino]benzoic acid, GLYCEROL, ... (6 entities in total)
• 機能のキーワード: magnesium binding, phosphoribosylpyrophosphate, prpp, inhibitor complex, tri-anthranilate analogue, tb structural genomics consortium, tbsgc, phosphoribosyltransferase, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Mycobacterium tuberculosis
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 78998.19

構造登録者

Evans, G.L.,Baker, E.N.,Lott, J.S.,TB Structural Genomics Consortium (TBSGC) (登録日: 2013-08-02, 公開日: 2014-05-21, 最終更新日: 2023-09-20)

主引用文献

Evans, G.L.,Gamage, S.A.,Bulloch, E.M.,Baker, E.N.,Denny, W.A.,Lott, J.S.
Repurposing the Chemical Scaffold of the Anti-Arthritic Drug Lobenzarit to Target Tryptophan Biosynthesis in Mycobacterium tuberculosis.
Chembiochem, 15:852-864, 2014

PubMed Abstract: The emergence of extensively drug-resistant strains of Mycobacterium tuberculosis (Mtb) highlights the need for new therapeutics to treat tuberculosis. We are attempting to fast-track a targeted approach to drug design by generating analogues of a validated hit from molecular library screening that shares its chemical scaffold with a current therapeutic, the anti-arthritic drug Lobenzarit (LBZ). Our target, anthranilate phosphoribosyltransferase (AnPRT), is an enzyme from the tryptophan biosynthetic pathway in Mtb. A bifurcated hydrogen bond was found to be a key feature of the LBZ-like chemical scaffold and critical for enzyme inhibition. We have determined crystal structures of compounds in complex with the enzyme that indicate that the bifurcated hydrogen bond assists in orientating compounds in the correct conformation to interact with key residues in the substrate-binding tunnel of Mtb-AnPRT. Characterising the inhibitory potency of the hit and its analogues in different ways proved useful, due to the multiple substrates and substrate binding sites of this enzyme. Binding in a site other than the catalytic site was found to be associated with partial inhibition. An analogue, 2-(2-5-methylcarboxyphenylamino)-3-methylbenzoic acid, that bound at the catalytic site and caused complete, rather than partial, inhibition of enzyme activity was found. Therefore, we designed and synthesised an extended version of the scaffold on the basis of this observation. The resultant compound, 2,6-bis-(2-carboxyphenylamino)benzoate, is a 40-fold more potent inhibitor of the enzyme than the original hit and provides direction for further structure-based drug design.

PubMed: 24623674
DOI: 10.1002/cbic.201300628

実験手法

X-RAY DIFFRACTION (1.96 Å)